Skip to main content
. 2022 May 12;12:874462. doi: 10.3389/fonc.2022.874462

Figure 3.

Figure 3

(A) PFS2 of PTCL with secondary CNS disease (n = 16) and with systemic relapse (n = 493). (B) OS2 of PTCL with secondary CNS disease (n = 16) and with systemic relapse (n = 493).